Upstream Bioprocessing Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Upstream Bioprocessing Market Analysis
The upstream bioprocessing market is expected to register a CAGR of 5.5% over the forecast period.
- The COVID-19 pandemic significantly impacted the upstream bioprocessing market, as drug manufacturers focused on developing vaccines and medications for COVID-19 diagnosis and treatment. The need for efficient development of new upstream bioprocesses became more crucial during the pandemic. This resulted in a surge in upstream bioprocessing rates, which contributed to market growth. However, as COVID-19 cases decline, the market is stabilizing, returning to pre-pandemic levels.
- Over the forecast period, the rising adoption of single-use upstream bioprocessing, commercial success and demand for biotherapeutics, and increasing research activities are expected to drive the market's growth. Advanced upstream bioprocessing technologies are essential in developing and scaling up manufacturing operations and analytical testing capabilities. These processes are crucial in the research activities to develop biosimilars, therapeutic peptides, and monoclonal antibodies. Upstream bioprocessing's contamination-free, safe, and efficient production further propels the market. With solid investments in R&D activities and a pipeline of therapeutics under development, upstream bioprocessing is expected to grow significantly.
- The increasing investment in research and development by phramceutical industry across the world is also expected to contribute to the growth of the market. For instance, according European Federation of Pharmaceutical Association the research and development expenditure incureeed in Europe by Pharmaceutical industry was EUR 42.53 billion (USD 44.72 billion) in 2022 and This is expected to increase to EUR 44.50 billion (USD 46.79 billion) in 2023. Such increase in R&D also creates need for the upsteam bioprocessing products and hence expected to propel the growth of the market.
- The launch of technologically advanced and innovative products also drives the market's growth. For example, Thermo Fisher Scientific launched its new Gibco Human Plasma-like Medium (HPLM) to provide researchers with a realistic view of cell growth within the human body. Nucleus Biologics launched Krakatoa, which is a creative, one of the first-to-market media makers that help researchers manufacture cell culture media at the point of use.
- Although the market has promising growth potential, operational challenges regarding upstream bioprocessing are expected to restrain the market's growth over the forecast period.
Upstream Bioprocessing Market Trends
Bioreactors/Fermenters is Expected to Witness Growth Over the Forecast Period
- The use of bioreactors/fermenters in upstream bioprocessing is expected to experience strong growth due to their widespread application in small and large-scale bioproduction. Bioreactors/fermenters play an essential role in any bioprocess, whether it involves degrading pollutants or producing substances such as food, feed, chemicals, drugs, and tissues/organs for biomedical purposes. These devices provide an optimal environment for cells to proliferate while also maintaining precise pH, temperature, and adequate gas supply and adding nutrients for successful growth maintenance.
- Several factors are driving the growth of this market segment over the forecast period. Increasing R&D expenditure and research activities worldwide are key drivers, along with the numerous benefits associated with bioreactors/fermenters. For instance, in March 2022, Insud Pharma announced an agreement with Fresenius Kabi, under which Fresenius Kabi will acquire 55% of mAbxience, the fully-fledged global biotech company of the Spanish group. This alliance is expected to accelerate the biotech unit of Insud Pharma, providing opportunities to mAbxience customers and increasing its research activities. In May 2022, Insud Pharma was expected to open a new R&D facility in Spain, further demonstrating the significant investments in R&D activities anticipated to drive growth in this market segment.
- Moreover, partnerships, mergers, acquisitions, and collaborations by leading players in the market will boost growth. For example, in May 2022, Lonza and Adva Biotechnology entered into a license agreement, with Lonza providing Adva with access to core intellectual property to enable the expansion of automated bioreactors globally. Through the agreement, Lonza also granted Adva a non-exclusive license to certain patents related to intelligent automation and bioreactor control. Such developments are expected to propel the growth of the bioreactors/fermenters market segment.
- Overall, due to factors such as increasing R&D expenditure, global research activities, and the various advantages associated with bioreactors/fermenters, this market segment is anticipated to experience significant growth over the forecast period.
North America is Expected to Dominate the Upstream Bioprocessing Market Over the Forecast Period
- Over the forecast period, North America is expected to dominate the upstream bioprocessing market. This growth is attributed to several factors, including increasing research and development spending, the presence of large-scale manufacturing units, the growing popularity of disposables, increasing healthcare expenditure, and a well-established healthcare infrastructure.
- For example, according to the Federal Research and Development (R&D) Funding: FY2022 report released in January 2022, funding for R&D is concentrated in a few federal departments and agencies. In FY2021, five agencies received 93.0% of total federal R&D funding, with the Department of Health and Human Services receiving 27.6%. The most significant dollar increases in R&D funding would be made to Health and Human Services, up to USD 7.7 billion (17.8%). Upstream bioprocessing is an essential step in developing vaccines, drug development, and clinical trials, making such a scenario expected to boost the market growth.
- Additionally, according to the Canadian Institute for Health Information (CIHI) November 2022 update, healthcare expenditure in the Canada is expected to reach USD 331 billion in 2022 compared to USD 308 billion in 2021. This increasing healthcare expenditure is expected to drive the demand for drugs, leading to growth in the demand for upstream bioprocessing and thereby driving the market growth.
- Furthermore, the initiatives of players in the region are also driving the growth of the upstream bioprocessing market. For instance, in November 2021, Bionova opened a USD 25.0 million single-use plant in Fremont, California, equipped with a 1,000 L Cytiva XDR upstream train. The company is also planning to add a 2,000 L Cytiva system by Q3'2022. Such developments are expected to drive market growth.
- Therefore, North America's growth in the upstream bioprocessing market is anticipated due to factors such as increasing research and development spending, the presence of large-scale manufacturing units, the growing popularity of disposables, increasing healthcare expenditure, and well-established healthcare infrastructure.
Upstream Bioprocessing Industry Overview
The upstream bioprocessing market is highly competitive and fragmented, with numerous companies operating globally and regionally. The competitive landscape includes both international and local companies that hold significant market shares. Key players in this market include Thermo Fisher Scientific Inc., Danaher Corporation (Cytvia), Corning, Inc., Merck KGaA, Eppendorf AG, Sartorius AG, Boehringer Ingelheim GmbH, Applikon Biotechnology, and CellGenix GmbH. These companies are well known for their innovative products, strong distribution networks, and comprehensive service offerings, which help them maintain a dominant position in the market.
Upstream Bioprocessing Market Leaders
-
Thermo Fisher Scientific Inc.
-
Corning, Inc
-
Merck KGaA
-
Sartorius AG
-
Danaher Corporation (Cytvia)
*Disclaimer: Major Players sorted in no particular order
Upstream Bioprocessing Market News
- April 2022: High Purity New England (HPNE) announced the launch of a new manufacturing facility, which represents a USD 10 million investment. The facility serves as HPNE's Specialty Manufacturing and Distribution Center and significantly increases the company's manufacturing capacity for single-use solutions.
- February 2022: Thermo Fisher Scientific invested USD 40 million to expand its single-use technology manufacturing facility in Millersburg, Pennsylvania. This expansion is part of the company's USD 650 million multi-year investment plan to enhance its capacity to provide flexible, scalable, and reliable bioprocessing production solutions.
Upstream Bioprocessing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Adoption of Single-use Upstream Bioprocessing
- 4.2.2 Commercial Success and Rising Demand for Biotherapeutics
-
4.3 Market Restraints
- 4.3.1 Operational Challenges Pertaining to Upstream Bioprocessing
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Product
- 5.1.1 Cell Culture Products
- 5.1.2 Bioreactors/Fermenters
- 5.1.3 Filters
- 5.1.4 Bioreactors Accessories
- 5.1.5 Other Products
-
5.2 By Usage Type
- 5.2.1 Single-Use
- 5.2.2 Multi-Use
-
5.3 By Mode
- 5.3.1 In-house
- 5.3.2 Outsourced
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Thermo Fisher Scientific Inc.
- 6.1.2 Danaher Corporation (Cytvia)
- 6.1.3 Corning, Inc.
- 6.1.4 Merck KGaA
- 6.1.5 Eppendorf AG
- 6.1.6 Sartorius AG
- 6.1.7 Boehringer Ingelheim GmbH
- 6.1.8 Entegris
- 6.1.9 Applikon Biotechnology
- 6.1.10 CellGenix GmbH
- 6.1.11 Getinge AB
- 6.1.12 Avantor
- 6.1.13 Cesco Bioengneering Co., Ltd.
- 6.1.14 Cellexus
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityUpstream Bioprocessing Industry Segmentation
As per the scope, upstream bioprocessing involves using living cells to obtain desired products. This process starts from early cell separation and cultivation to cell culture expansion to harvest the final product.
The upstream bioprocessing market is segmented by product (cell culture products, bioreactors/fermenters, filters, bioreactors accessories, and other products), usage type (single-use and multi-use), mode (in-house and outsourced), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Product | Cell Culture Products | |
| Bioreactors/Fermenters | ||
| Filters | ||
| Bioreactors Accessories | ||
| Other Products | ||
| By Usage Type | Single-Use | |
| Multi-Use | ||
| By Mode | In-house | |
| Outsourced | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Upstream Bioprocessing Market Research FAQs
What is the current Upstream Bioprocessing Market size?
The Upstream Bioprocessing Market is projected to register a CAGR of 5.5% during the forecast period (2024-2029)
Who are the key players in Upstream Bioprocessing Market?
Thermo Fisher Scientific Inc., Corning, Inc, Merck KGaA, Sartorius AG and Danaher Corporation (Cytvia) are the major companies operating in the Upstream Bioprocessing Market.
Which is the fastest growing region in Upstream Bioprocessing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Upstream Bioprocessing Market?
In 2024, the North America accounts for the largest market share in Upstream Bioprocessing Market.
What years does this Upstream Bioprocessing Market cover?
The report covers the Upstream Bioprocessing Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Upstream Bioprocessing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Upstream Bioprocessing Industry Report
Statistics for the 2024 Upstream Bioprocessing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Upstream Bioprocessing analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
